Evidence map›Paper›PMID 26371611›Full record

ArticleJournal of acquired immune deficiency syndromes (1999)2015

Time and Money: The True Costs of Health Care Utilization for Patients Receiving "Free" HIV/Tuberculosis Care and Treatment in Rural KwaZulu-Natal.

Natsayi Chimbindi, Jacob Bor, Marie-Louise Newell, Frank Tanser, Rob Baltussen, Jan Hontelez, Sake J de Vlas, Mark Lurie, Deenan Pillay, Till Bärnighausen

Abstract read
In one paragraph

Article in Journal of acquired immune deficiency syndromes (1999), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 66 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
66citing papers in PubMed, 4 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

66 citing papers in PubMed, 4 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

6 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Natsayi Chimbindi*Wellcome Trust Africa Centre for Health and Population Studies, University of KwaZulu-Natal, South Africa; †School of Public Health, University of the Witwatersrand, Johannesburg, South Africa; ‡Department of Global Health, School of Public Health, Boston University, Boston, MA; §Faculty of Medicine and Faculty of Human and Social Sciences, University of Southampton, Southampton, United Kingdom; ‖Nijmegen International Center for Health System Analysis and Education (NICHE), Department of Primary and Community Care, Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands; ¶Department of Public Health, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands; #Department of Epidemiology and International Health Institute, Brown University School of Public Health, Providence, RI; **Department of Virology, University College London, London, United Kingdom; and ††Department of Global Health and Population, Harvard T.H. Chan School of Public Health, Boston, MA.
Jacob Bor
Marie-Louise Newell
Frank Tanser
Rob Baltussen
Jan Hontelez
Sake J de Vlas
Mark Lurie
Deenan Pillay
Till Bärnighausen

Funding

Causal Pathways to population health impact of HIV antiretroviral treatmentR01HD084233 · NICHD · UNIVERSITY OF KWAZULU-NATAL · PI BARNIGHAUSEN, TILL, TANSER, FRANK COURTENEY · 2015 to 2021
$2.3M
Impact of Antiretroviral Therapy on HIV Epidemic DynamicsR01MH083539 · NIMH · BROWN UNIVERSITY · PI LURIE, MARK NATHAN · 2009 to 2012
$2.2M
Understanding causal pathways of HIV acquisition and transmission: a multi-level,R01HD058482 · NICHD · UNIVERSITY OF KWAZULU-NATAL · PI BARNIGHAUSEN, TILL, TANSER, FRANK COURTENEY · 2008 to 2012
$1.2M
Economic, health, and behavioral dimensions of HIV treatment scale-upK01MH105320 · NIMH · BOSTON UNIVERSITY MEDICAL CAMPUS · PI BOR, JACOB · 2015 to 2018
$613k
Medical Research Council MR/K006584/1NICHD NIH HHS 1R01-HD058482-01NICHD NIH HHS R01 HD058482NICHD NIH HHS R01 HD084233NIMH NIH HHS 1K01MH105320-01A1NIMH NIH HHS 1R01MH083539NIMH NIH HHS K01 MH105320NIMH NIH HHS R01 MH083539Wellcome Trust 082384/Z/07/ZWellcome Trust 097410
6 · The paper itself

Abstract

backgroundHIV and tuberculosis (TB) services are provided free of charge in many sub-Saharan African countries, but patients still incur costs.

methodsPatient-exit interviews were conducted in primary health care clinics in rural South Africa with representative samples of 200 HIV-infected patients enrolled in a pre-antiretroviral treatment (pre-ART) program, 300 patients receiving antiretroviral treatment (ART), and 300 patients receiving TB treatment. For each group, we calculated health expenditures across different spending categories, time spent traveling to and using services, and how patients financed their spending. Associations between patient group and costs were assessed in multivariate regression models.

resultsTotal monthly health expenditures [1 USD = 7.3 South African Rand (ZAR)] were ZAR 171 [95% confidence interval (CI): 134 to 207] for pre-ART, ZAR 164 (95% CI: 141 to 187) for ART, and ZAR 122 (95% CI: 105 to 140) for TB patients (P = 0.01). Total monthly time costs (in hours) were 3.4 (95% CI: 3.3 to 3.5) for pre-ART, 5.0 (95% CI: 4.7 to 5.3) for ART, and 3.2 (95% CI: 2.9 to 3.4) for TB patients (P < 0.01). Although overall patient costs were similar across groups, pre-ART patients spent on average ZAR 29.2 more on traditional healers and ZAR 25.9 more on chemists and private doctors than ART patients, whereas ART patients spent ZAR 34.0 more than pre-ART patients on transport to clinics (P < 0.05 for all results). Thirty-one percent of pre-ART, 39% of ART, and 41% of TB patients borrowed money or sold assets to finance health care.

conclusionsPatients receiving nominally free care for HIV/TB face large private costs, commonly leading to financial distress. Subsidized transport, fewer clinic visits, and drug pick-up points closer to home could reduce costs for ART patients, potentially improving retention and adherence. Large expenditure on alternative care among pre-ART patients suggests that transitioning patients to ART earlier, as under HIV treatment-as-prevention policies, may not substantially increase patients' financial burden.

Indexed as

Health Care CostsAdultAfrica South of the SaharaBanking, PersonalFemaleGovernment ProgramsHIV InfectionsHumansMaleMiddle AgedTime FactorsTuberculosisYoung Adult

Identifiers

PMID26371611
PMCPMC4748708

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.